Sotoxen 120mg (Sotorasib)

Sotoxen 120mg (Sotorasib) is a drug manufactured by Everest Pharmaceuticals – Bangladesh, with the main ingredient Sotorasib has the effect of treating locally advanced or metastatic non-small cell lung cancer, the drug helps prevent cancer cells. develop and spread.

What is Sotoxen 120mg (Sotorasib)?

• Sotoxen 120mg (Sotorasib) is a drug manufactured by Everest Pharmaceuticals – Bangladesh, with the main ingredient Sotorasib has the effect of treating locally advanced or metastatic non-small cell lung cancer, the drug helps prevent cancer cells. develop and spread.

Ingredients of Sotoxen 120mg (Sotorasib)

• Sotorasib 120mg.

Dosage forms

• Tablets.

What is lung cancer?

• Lung cancer is the uncontrolled growth of abnormal cells in one or both lungs, usually cells in the lining of the airways. These abnormal cells do not develop into healthy lung tissue but divide rapidly and form tumors that interfere with lung function.

Uses and indications of Sotoxen 120mg (Sotorasib)

• Sotoxen 120mg (Sotorasib) is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) caused by KRAS G12C in adults who have received at least one prior systemic therapy.

Dosage – Dosage of Sotoxen 120mg (Sotorasib)

• How to use:
  • Drugs for oral use
• Dosage:
  • Medicines used as prescribed by the doctor.

Contraindications of Sotoxen 120mg (Sotorasib)

• Do not use for people who are sensitive to any of the ingredients.

Precautions while using Sotoxen 120mg (Sotorasib)

• Use with caution in women who are pregnant or planning to become pregnant
• Use caution in patients with liver problems
• People with lung or breathing problems other than lung cancer

Use for pregnant or lactating women

• Pregnant or lactating women consult a doctor

Use for drivers and machine operators

• Use caution when using the drug with subjects who drive and operate heavy machinery, because the drug can cause dizziness, loss of ataxia, ..

Side effects of Sotoxen 120mg (Sotorasib)

• Get emergency medical help if you have signs of an allergic reaction: hives; shortness of breath; swelling of the face, lips, tongue, or throat.
• Sotoxen 125mg (Sotorasib) can cause fatal breathing problems. Get emergency medical help if you have a new or worsening fever, cough, or shortness of breath.
• Severe persistent nausea, vomiting or diarrhea;
• liver problems–nausea, vomiting, loss of appetite, stomach pain (upper right), fatigue, bruising or bleeding, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes ).
• Frequent:
  • Nausea, diarrhea;
  • Cough;
  • Life problems;
  • Pain in bones, joints, or muscles;
  • Weariness.

• Inform your doctor about unwanted effects encountered when using.

Interact

• Acid reducing agent:
  • Concomitant administration of Sotorasib 120mg with gastric acid reducers reduces sotorasib concentrations, which may decrease the effectiveness of sotorasib. Avoid co-administration of LUMAKRAS with proton pump inhibitors (PPIs), H2-receptor antagonists and locally acting antacids. If co-administration with an antacid cannot be avoided, administer Sotorasib 120mg 4 hours before or 10 hours after a topical antacid
• Strong CYP3A4 Inducers:
  • Co-administration of Sotorasib 120mg with a strong CYP3A4 inducer reduces sotorasib concentrations which may decrease the effectiveness of sotorasib. Avoid co-administration of Sotorasib 120mg with strong CYP3A4 inducers.

• Effect of Sotorasib 120mg on other medicines
  • CYP3A4 Substrates
    Co-administration of Sotorasib 120mg with a CYP3A4 substrate reduces its plasma concentrations, which may decrease the effectiveness of the substrate. Avoid co-administration of Sotorasib 120mg with CYP3A4-sensitive substrates, as minimal concentration changes may lead to substrate therapy failure. If co-administration cannot be avoided, increase the dose of the sensitive CYP3A4 substrate according to its Prescribing Information.
  • P-Glycoprotein (P-gp) Substrates
    Co-administration of Sotorasib 120mg with P-gp substrate (digoxin) increases plasma concentrations of digoxin, possibly increasing the adverse reactions of digoxin. Avoid co-administration of Sotorasib 120mg with a P-gp substrate where minimal concentration changes can lead to serious toxicity. If co-administration cannot be avoided, reduce the dose of the P-gp substrate in accordance with its Prescribing Information.

Overdose and treatment

• If an overdose occurs, notify your doctor immediately, or if you see unusual symptoms, you need to go to the hospital for timely treatment.

Preserve

• Store at a cool temperature below 30 degrees Celsius.
• Keep out of reach of CHILDREN.

Packing

• Box of 56 tablets.

Producer

• Everest Pharmaceuticals – Bangladesh.